WP5 JA1 Pilot Pazopanib Report+Appendix

The final version of the WP5 JA1 pilot assessment using the draft model for Rapid Relative Effectiveness Assessment of Pharmaceuticals and guidelines. The joint assessment involved the participation of 22 HTA organisations as authors on different domains or as reviewers. Find the full list on page 16 in side the report. The final version of the WP5 […]

Responses to Public consultation of the draft Project Plan on Endobarrier

The draft Project Plan on “Duodenal-jejunal bypass sleeve (Endobarrier®) for the treatment of obesity” was open to public consultation between 21 March and 4 April 2013. This document presents the comments through the public consultation. The aim of the Project Plan is to provide an overview on the planned processes, the scope, the scientific methods […]

Public consultation of the Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals

This document presents the public consultation of WP5 Joint Action Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals.   The Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals under production by Work Package 5 Joint Action 1 were open for public consultation during the following periods:   29 June – 10 September 2012 […]

Methodological guideline for REA of pharmaceuticals: Composite endpoints

This guideline provides a set of recommendations for the selection and assessment of clinical endpoints when completing a Relative Effectiveness Assessment (REA) of pharmaceuticals. A composite endpoint (CE) consists of two or more single events combined in one outcome that should represent an overall clinically relevant and valid measure of clinical benefit due to treatment. […]

Methodological guideline for REA of pharmaceuticals: Internal validity

This guideline focuses on the assessment of the risk of bias of randomized controlled trials (RCTs), the most relevant trials for relative effectiveness assessment (REA) of pharmaceuticals. The quality assessment of non-randomized and diagnostic accuracy studies will be elaborated in separate guidelines. Likewise, a separate guideline deals with the problem of assessing applicability. Internal validity describes […]

List of comments for the WP5 JA1 Pilot Pazopanib Report

The list of comments for the WP5 JA1 Pilot Pazopanib Report. The list provides the contact information of all the organisations that properly submitted their contributions. The list of comments for the WP5 JA1 Pilot Pazopanib Report. The list provides the contact information of all the organisations that properly submitted their contributions. This document is […]

List of commentators for the WP5 JA1 Pilot Pazopanib Report

The list with commentators provides the contact information of all the organisations that properly submitted contributions. The list with commentators provides the contact information of all the organisations that properly submitted contributions. List of commentators for the WP5 JA1 Pilot Pazopanib Report